Last reviewed · How we verify

Antiretroviral medications

French National Agency for Research on AIDS and Viral Hepatitis · Phase 3 active Small molecule

Antiretroviral medications is a Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently in Phase 3 development for HIV-1 infection, HIV-2 infection.

Antiretroviral medications inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells.

Antiretroviral medications inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells. Used for HIV-1 infection, HIV-2 infection.

At a glance

Generic nameAntiretroviral medications
SponsorFrench National Agency for Research on AIDS and Viral Hepatitis
Drug classAntiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)
TargetHIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Antiretrovirals work through multiple mechanisms depending on drug class: reverse transcriptase inhibitors block viral RNA-to-DNA conversion, protease inhibitors prevent viral protein maturation, integrase inhibitors block viral DNA integration into the host genome, and entry inhibitors prevent viral attachment or fusion with CD4+ cells. These drugs are typically used in combination (highly active antiretroviral therapy, HAART) to suppress viral load and restore immune function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Antiretroviral medications

What is Antiretroviral medications?

Antiretroviral medications is a Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) drug developed by French National Agency for Research on AIDS and Viral Hepatitis, indicated for HIV-1 infection, HIV-2 infection.

How does Antiretroviral medications work?

Antiretroviral medications inhibit HIV replication by targeting viral enzymes or blocking viral entry into CD4+ T cells.

What is Antiretroviral medications used for?

Antiretroviral medications is indicated for HIV-1 infection, HIV-2 infection.

Who makes Antiretroviral medications?

Antiretroviral medications is developed by French National Agency for Research on AIDS and Viral Hepatitis (see full French National Agency for Research on AIDS and Viral Hepatitis pipeline at /company/french-national-agency-for-research-on-aids-and-viral-hepatitis).

What drug class is Antiretroviral medications in?

Antiretroviral medications belongs to the Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) class. See all Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) drugs at /class/antiretroviral-agents-multiple-classes-nrtis-nnrtis-pis-instis-entry-inhibitors.

What development phase is Antiretroviral medications in?

Antiretroviral medications is in Phase 3.

What are the side effects of Antiretroviral medications?

Common side effects of Antiretroviral medications include Nausea, Diarrhea, Headache, Lipodystrophy, Hepatotoxicity, Peripheral neuropathy.

What does Antiretroviral medications target?

Antiretroviral medications targets HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, CXCR4, gp120/gp41 and is a Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors).

Related